Phase 3 Myasthenia Gravis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 18 and 85 years old and have been diagnosed with generalized Myasthenia Gravis (gMG)
- A blood test has confirmed you have a specific antibody associated with Myasthenia Gravis (called AChR+ antibody)
- Your Myasthenia Gravis is at a moderate to severe level, and your doctor does not expect you to need a breathing machine during the study
- Your diagnosis has been confirmed by at least one of: a nerve/muscle electrical test, a positive response to a short-acting medication test, or noticeable improvement in your symptoms when taking Myasthenia Gravis medication
- Your Myasthenia Gravis symptoms significantly affect your daily life (based on a specific score), and most of those difficulties are caused by symptoms other than eye-related issues
- You have been receiving at least one established treatment for Myasthenia Gravis for at least 6 months before joining the study (this could include certain immune-suppressing drugs, regular plasma treatments, an approved FcRn-blocking drug, rituximab, or other approved Myasthenia Gravis treatments — but not complement inhibitors)
- You have received, or are willing to receive, certain vaccines (against meningitis and pneumococcal infections) at least 2 weeks before starting the study treatment (confirm with trial site for US-specific requirements)
Who may not be able to join:
- You have recently received certain treatments, including: IVIG or plasma exchange in the past month; rituximab in the past 6 months; eculizumab in the past 2 months; ravulizumab or other complement inhibitors in the past 3 months; efgartigimod or similar therapies in the past 3 months; or you have had, or are planning, a thymus gland removal surgery within 6 months
- You currently have a significant active or long-term uncontrolled bacterial, viral, or fungal infection
- You have active Hepatitis B, active Hepatitis C, or HIV with a serious related condition or very low immune cell count (confirm with trial site)
- You are pregnant, breastfeeding, or planning to become pregnant
- You are a woman capable of becoming pregnant and are not willing or able to use effective contraception during the study and for one week after the last dose
- You have had a serious infection requiring hospitalisation or injected antibiotics within the 14 days before starting the study treatment
- You have a history of repeated serious infections caused by certain bacteria (such as meningococcal or pneumococcal infections)
- You have had a fever of 38°C (100.4°F) or higher within the 7 days before starting the study treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-888-669-6682
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change from baseline to Month 6 in Myasthenia Gravis Activity of Daily Living (MG-ADL) total score
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.